0001493152-26-012992
SEC filingDermata Therapeutics, Inc. reported a net loss of $7.6 million for the fiscal year ended December 31, 2025, an improvement from a net loss of $12.3 million in the prior year. The company's strategic shift from prescription drug development to direct-to-consumer (DTC) and business-to-business (B2B) skincare products, announced in September 2025, is central to its forward-looking strategy. Total operating expenses were $7.8 million, down from $12.5 million in 2024, primarily due to decreased clinical trial costs following the completion of the Phase 3 STAR-1 trial for XYNGARI. Research and development expenses decreased to $2.9 million from $8.2 million, while selling, general and administrative expenses increased to $4.8 million from $4.3 million, reflecting initial marketing investments for the upcoming Tome skincare brand launch. The company ended the period with $7.5 million in cash and cash equivalents, having raised $12.1 million in net financing proceeds during the year. Management believes existing cash will fund operations into the first quarter of 2027, with the first commercial product, the Tome Foundational Treatment, planned for launch in mid-2026.
Dermata Therapeutics, Inc. reported a net loss of $7.6 million for the fiscal year ended December 31, 2025, compared to a net loss of $12.3 million for the prior year. This improvement of $4.7 million was primarily driven by a significant reduction in operating expenses. Total operating expenses decreased to $7.8 million from $12.5 million in 2024. The net loss per share of common stock, both basic and diluted, was $8 for both 2025 and 2024. The company's strategic repositioning, announced in September 2025, involves a shift from developing prescription acne treatments to developing and commercializing direct-to-consumer (DTC) and business-to-business (B2B) skincare products under the new Tome brand. This shift followed the successful completion of the Phase 3 STAR-1 clinical trial for its former lead prescription candidate, XYNGARI (DMT310), in March 2025.
The company is a pre-commercial stage entity and has not generated any revenue from product sales to date. Its operations have been funded primarily through the sale of equity and debt securities. The business model is transitioning toward generating future revenue from the sale of skincare products. The company plans to launch its first commercial product, the Tome Foundational Treatment powered by Bioneedle, in the middle of 2026, with the Tome Clearing Treatment for acne to follow shortly thereafter. Revenue generation is dependent on the successful commercial launch and market acceptance of these initial products.
As a company with no revenue, traditional margin analysis is not applicable. The focus is on managing operating expenses, which totaled $7.8 million for the year. Research and development expenses decreased by $5.3 million to $2.9 million, primarily due to the completion of the STAR-1 clinical trial. Selling, general and administrative expenses increased by $0.5 million to $4.8 million, driven by $0.7 million in marketing expenses related to preparing for the Tome brand launch, partially offset by lower personnel-related costs. The company's accumulated deficit as of December 31, 2025, was $73.2 million.
Net cash used in operating activities was $7.8 million for the year ended December 31, 2025. Net cash provided by financing activities was $12.1 million, primarily from equity financings including a January 2025 PIPE, a March 2025 warrant inducement, a December 2025 PIPE, and ATM sales. This resulted in a net increase in cash and cash equivalents of $4.4 million for the year. The balance sheet as of December 31, 2025, shows total assets of $7.9 million, consisting primarily of $7.5 million in cash and cash equivalents and $0.3 million in prepaid expenses. Total liabilities were $1.6 million, and total stockholders' equity was $6.2 million. The company believes its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2027.
The company's near-term strategy centers on the development and commercialization of its Tome skincare products. Key planned activities include the launch of the Tome Foundational Treatment in mid-2026 and the subsequent launch of the Tome Clearing Treatment. The company intends to commercialize these products through a dual-channel strategy combining DTC e-commerce and B2B professional channels targeting skincare professionals. Management acknowledges significant risks and uncertainties, including its lack of operating history as a commercial company, intense competition in the skincare industry, dependence on a single supplier (Reka-Farm LLC) for its key raw material (Spongilla lacustris), and the need for additional capital to fully execute its business plan. The report from the independent registered public accounting firm contains an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.